Source link : https://newshealth.biz/health-news/sglt2-inhibitors-progressing-to-new-standard-after-tavi/
CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, reduces the risk for death and heart failure events by almost 30%, the randomized DapaTAVI trial shows. The two questions addressed in this “pragmatic” trial […]
The post SGLT2 Inhibitors Progressing to New Standard After TAVI first appeared on News Health.
Author : News Health
Publish date : 2025-04-03 13:34:00
Copyright for syndicated content belongs to the linked Source.
in Health